General Federal Contracts — August 09, 2026

SIGA's firm-fixed-price contract for smallpox antiviral development provides multi-year revenue visibility through 2029, with $447.2M already outlayed, indicating strong government commitment and cash flow.

The one-year VA contract for medical disability exams in the Southeast, with $196.6M outlayed, signals sustained demand for VA medical services, but completion limits forward growth visibility.

Non-competed, time-and-materials contract for legal services has a 6-month base period and high pricing risk, with potential total value of $244M if options are exercised, but nonprofit status and lack of public financial data temper confidence.

SIGA's fixed-price contract carries medium pricing risk; cost overruns could impact margins despite the $447.2M already outlayed.

OUR RESCUE's time-and-materials contract has high pricing risk due to its non-competed nature and short base period, with potential for cost overruns.

Significant concentration in HHS awards (SIGA and OUR RESCUE) totaling $784.6M, exposing the stream to HHS budget priorities and potential policy shifts.

SIGA's contract with HHS/BARDA positions it for follow-on biodefense contracts, given the agency's mission and long-term commitment to antiviral development.

Leidos' QTC Medical Services could see follow-on VA contracts for medical disability exams in other regions, given the completion of the Southeast delivery order.

OUR RESCUE's non-competed bridge contract suggests a specialized capability, potentially leading to a competitive re-solicitation or direct extension, but with limited visibility.

SIGA's $626.5M HHS/BARDA contract underscores government investment in countermeasures, with a long-term contract to 2029.

QTC Medical Services' $209.2M VA delivery order indicates sustained demand for medical disability exams, despite a short performance period.

{"entity" => "SIGA Technologies", "reason" => "Multi-year revenue stream from $626.5M HHS contract", "trigger" => "Quarterly earnings for cost performance; BARDA option exercises"}

{"entity" => "Leidos Holdings", "reason" => "VA medical services contract completion, potential follow-ons", "trigger" => "VA re-compete announcements for disability exams"}

{"entity" => "OUR RESCUE", "reason" => "Non-competed bridge contract with high execution risk", "trigger" => "Option exercise decision by February 2027"}